Rare diseases Marathon sells Duchenne drug to PTC PTC says it will make changes to the price after abandoned launch last month.
News Marathon halts launch of Duchenne drug after price outcry Company says it will listen to concerns of patient advocates
Patients Biosimilars & patient access independent of geographies or s... Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
